Retinal Vein Occlusion Treatment Market By Treatment Type (Anti-VEGF Therapy, Corticosteroid Therapy, Laser Therapy, Investigational & Disease-Modifying Therapies); By Anti-VEGF Molecule Type (Aflibercept, Faricimab, Ranibizumab, Bevacizumab, Biosimilar Anti-VEGF Agents); By Disease Type (Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion); By Treatment Setting (Retina Specialty Centers, Ophthalmology Clinics, Hospitals, Ambulatory Retina Care Settings); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Clinic-Based Procurement, Retail Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Retinal Vein Occlusion Treatment Market: Longer-Interval Anti-VEGF, Biosimilar Pressure, and Real-World Injection Burden Redefine Retina Care

The Global Retinal Vein Occlusion (RVO) Treatment Market was valued at USD 2.57 billion in 2025 and is projected to reach USD 3.90 billion by 2032, growing at a CAGR of 6.1%, according to Strategic Market Research.

 

Retinal vein occlusion treatment demand is rising as more older patients with hypertension are diagnosed and managed in retina clinics.

 

A global meta-analysis estimated that 28.06 million people aged 30–89 had retinal vein occlusion in 2015. Branch retinal vein occlusion accounted for 23.38 million cases, while central retinal vein occlusion accounted for 4.67 million. The pooled cumulative incidence reached 0.86% over five years and 1.63% over ten years. Hypertension had the strongest reported risk association, with an odds ratio of 2.82.

 

Not every patient with RVO needs continued treatment. Demand is concentrated among those who develop macular edema with vision loss. The Royal College of Ophthalmologists estimates that macular edema causes visual impairment in approximately 11,600 BRVO patients and 5,700 CRVO patients each year in England and Wales.

 

RVO prevalence rises from 0.7% among people below age 60 to 4.6% among those aged 80 and above. WHO’s estimate of 1.4 billion adults aged 30–79 living with hypertension in 2024 adds a large long-term risk pool.

 

Market growth will depend less on the total number of people with RVO and more on how many develop macular edema, start treatment, stay on therapy, and receive reimbursement.

 

Anti-VEGF Therapy Will Remain the Revenue Foundation

Anti-VEGF treatment holds the largest commercial position because macular edema drives most vision-related intervention in RVO. Royal College guidance identifies ranibizumab, aflibercept, and bevacizumab as widely used therapies for CRVO-related macular edema.

The CRYSTAL study found that 37% of patients achieved stable visual acuity after three monthly injections, while a substantial group required six consecutive monthly injections. The result supports significant first-year treatment demand but also confirms that injection requirements differ widely between patients.

Aflibercept strengthened the anti-VEGF position in BRVO through the VIBRANT study. At six months, 53% of aflibercept-treated patients gained at least 15 letters, compared with 27% of patients treated with laser.

SCORE2 kept lower-cost bevacizumab commercially relevant by randomizing 362 patients with CRVO or hemiretinal vein occlusion-related macular edema. Monthly bevacizumab was noninferior to aflibercept for visual acuity at six months.

Anti-VEGF therapy will remain the main treatment option, but branded products will need more than strong clinical results to hold share. Longer dosing intervals, reimbursement coverage, ease of use, and physician familiarity will matter just as much.

 

Real-World Data Reveal a Large Diagnosis-to-Treatment Gap

An analysis of the American Academy of Ophthalmology’s IRIS Registry identified 304,558 patients with RVO and macular edema between 2015 and 2021.

Within one year, 192,602 patients, or 63.2%, received at least one anti-VEGF injection. The remaining 37% had no documented anti-VEGF treatment. Treatment rates reached approximately 70% among patients presenting with visual acuity worse than 20/40 to 20/200 but were lower among patients at either end of the visual-acuity range.

The untreated share shows that many diagnosed patients do not enter anti-VEGF treatment. In practice, this can reflect milder disease, limited access to retina specialists, reimbursement barriers, missed appointments, or delays in follow-up.

New approvals alone will not convert the full RVO population into treated patients. Growth also depends on whether patients reach retina specialists early, return for follow-up, and remain on therapy after diagnosis.

 

Long-Term Injection Persistence Creates a Chronic Revenue Base

A Vestrum Health Retina database study followed 22,365 BRVO eyes and 18,064 CRVO eyes treated with anti-VEGF therapy.

Patients received an average of 6.9 injections for BRVO and 7.0 for CRVO during the first year. By the fifth year, annual injections had declined to 3.7 for BRVO and 3.9 for CRVO.

Visual gains also weakened over time. Mean improvement for BRVO declined from 11.5 letters at month 12 to 8.2 letters at month 60. CRVO gains declined from 9.7 letters to 5.3 letters over the same period.

Treatment remained active for many patients. Among eyes with available fifth-year data, 68% of BRVO eyes and 71% of CRVO eyes received at least one anti-VEGF injection.

These data show that RVO often requires ongoing treatment rather than a brief course of care. Revenue can continue over several years, although fewer injections over time and smaller visual gains make longer-lasting treatment options more important.

 

Clinic Capacity Is Increasing the Commercial Value of Longer Intervals

The Vestrum data indicate that patients typically receive about seven injections during the first treatment year, while the IRIS Registry identified more than 192,000 treated RVO patients within a six-year period.

High injection volumes strain retina practices. Each treatment visit requires imaging, scheduling, staff time, procedure capacity, and follow-up. Patients who miss appointments are less likely to stay on treatment, which reduces the number of patients completing ongoing therapy.

Longer dosing intervals can ease pressure on busy retina clinics by reducing the number of injection visits required each year. Fewer appointments may also make it easier for patients and caregivers to keep up with treatment.

Longer dosing intervals matter commercially because they can ease pressure on busy retina clinics. In high-volume practices, products that reduce the number of annual injections without sacrificing disease control are likely to be more attractive to physicians and patients.

 

Vabysmo Has Established a Second Branded Durability Franchise

The FDA approved Roche’s Vabysmo for macular edema following RVO in October 2023 based on the BALATON and COMINO phase 3 studies. The European Commission followed with approval in July 2024. The clinical program included more than 1,200 people with macular edema associated with branch and central retinal vein occlusion.

At 24 weeks, monthly faricimab produced visual-acuity gains that were noninferior to aflibercept. Longer-term results strengthened the commercial case. By 72 weeks, nearly 60% of BALATON patients and approximately 48% of COMINO patients reached treatment intervals of three or four months.

An FDA label update in April 2026 added support for treatment beyond the initial six-month period. The update gives physicians clearer regulatory backing for continued use in a disease where many patients need retreatment after the loading phase.

Reimbursement has also widened. NICE recommended faricimab for RVO-related macular edema in September 2024 and listed a price of £857 per vial before a confidential NHS discount. Ontario introduced public funding for the indication in August 2025.

Roche has moved Vabysmo beyond a clinical alternative and into a reimbursed durability competitor. Continued share gains will depend on whether extended intervals reduce clinic burden enough to justify its cost against aflibercept, bevacizumab, and biosimilars.

 

Eylea HD Is Protecting the Aflibercept Franchise Through Longer Dosing

The FDA approved aflibercept 8 mg for macular edema following RVO on November 19, 2025. The approved schedule allows dosing up to every eight weeks after the initial monthly period.

The QUASAR phase 3 trial met its 36-week primary endpoint. Eylea HD administered every eight weeks after three or five monthly doses produced noninferior visual gains compared with Eylea 2 mg administered every four weeks.

Bayer secured European Commission authorization in January 2026 for Eylea 8 mg in macular edema following branch, central, and hemiretinal vein occlusion.

Week-64 QUASAR data strengthened the durability position. More than 60% of patients receiving aflibercept 8 mg reached a final assigned interval of at least four months, while 40% reached five months. Patients receiving three initial monthly injections required an average of 8.4 injections through week 64, compared with 11.7 injections for Eylea 2 mg.

The American Academy of Ophthalmology included the FDA approval in its June 2026 Retinal Vein Occlusions Preferred Practice Pattern update.

Eylea HD gives Regeneron and Bayer a direct response to Vabysmo’s interval advantage. The product is positioned to protect the aflibercept franchise by moving existing prescribers toward higher-dose treatment before biosimilars further weaken Eylea 2 mg pricing.

 

Biosimilars Are Increasing Payer Control Over Drug Selection

The FDA approved Yesafili and Opuviz in May 2024 as the first interchangeable biosimilars to Eylea. Their approved indications include macular edema following RVO.

Interchangeability makes it easier for payers and pharmacy systems to favor lower-cost aflibercept products as launches expand and patent, supply, and contracting barriers ease.

Bevacizumab remains an additional pricing constraint. SCORE2 established it as a credible lower-cost benchmark in CRVO and hemiretinal vein occlusion, even though it remains off-label in many markets.

Biosimilars are likely to gain the most traction in markets where payers focus heavily on drug acquisition cost. Branded products will need to show clear advantages in dosing frequency, label breadth, real-world performance, or reimbursement to defend share.

 

India Shows How Price Competition Can Expand Treatment Access

Bayer reduced the listed price of Eylea 2 mg in India by approximately 44% in April 2026, from Rs. 53,141 to Rs. 29,998.

Zydus launched Anyra, a ranibizumab biosimilar, in February 2026 for major retinal disorders. The launch adds a lower-cost anti-VEGF option in a market where out-of-pocket spending can restrict treatment initiation and long-term persistence.

RVO treatment often requires repeated injections in the first year, followed by ongoing retreatment for many patients. With patients receiving about seven injections on average in year one, even moderate per-dose price differences can materially affect annual treatment affordability.

Lower prices and biosimilar competition can expand access, especially in markets where out-of-pocket costs remain high. The trade-off is lower revenue per injection. In India, market growth is more likely to come from higher treatment uptake and better follow-up adherence than from premium-priced products alone.

 

The United States Will Lead Revenue but Face Franchise Erosion

The United States is the largest RVO treatment market, supported by broad access to retina specialists, Medicare Part B coverage, high injection volumes, and large real-world data registries.

Regeneron reported U.S. Eylea HD net sales of USD 1.6 billion in 2025, increasing by 36%. However, combined U.S. sales of Eylea HD and Eylea declined by 27% to USD 4.4 billion.

The shift continued during the first quarter of 2026. Eylea HD sales increased by 52% to USD 468 million, while combined Eylea HD and Eylea sales declined by 10% to USD 941 million.

These figures cover several retinal diseases rather than RVO alone, but they identify the direction of the aflibercept franchise. High-dose conversion is growing while the older Eylea base faces biosimilar pressure, competition, and pricing erosion.

The U.S. market will continue to generate the largest branded revenue, but growth will come from converting patients to longer-duration products rather than expanding the older anti-VEGF base.

 

Vabysmo Is Becoming the Main Branded Challenger to Aflibercept

Roche reported Vabysmo sales of CHF 2.9 billion in 2025 across its approved retinal indications. RVO represents only part of this total, but the indication broadens the product’s reach across retina practices already using it for wet age-related macular degeneration and diabetic macular edema.

Roche’s competitive position is supported by FDA and European RVO approvals, 72-week interval data, the April 2026 U.S. label update, NICE support, and Ontario public funding.

Vabysmo can grow without displacing aflibercept across the full RVO market. Its strongest opportunity is in patients who need longer dosing intervals, have persistent disease activity, or are switched from another anti-VEGF treatment.

Roche has built a multi-indication retina franchise capable of competing for the same clinic capacity and reimbursement budgets as Eylea HD. Vabysmo and aflibercept 8 mg will define the branded durability segment through the remainder of the forecast period.

 

Europe Will Reward Durability Only When It Reduces System Costs

A European systematic review estimated RVO prevalence at 0.7% among people aged 55 and older. The number of affected people in the European Union is projected to increase from approximately 900,000 to 1.1 million by 2050.

The aging population supports long-term treatment demand, but national health systems maintain strict control over drug pricing and reimbursement. NICE’s September 2024 recommendation for Vabysmo included a confidential discount, reflecting the need for branded products to compete on cost-effectiveness rather than clinical performance alone.

European Commission approvals for Vabysmo in July 2024 and Eylea 8 mg in January 2026 give physicians two longer-interval branded options. Actual uptake will vary according to national health technology assessments, biosimilar policies, clinic capacity, and negotiated prices.

European uptake of premium therapies will depend on whether fewer injections translate into lower overall treatment costs for public health systems. If the budget impact remains unclear, bevacizumab and biosimilar aflibercept are likely to remain the preferred lower-cost options.

 

Asia-Pacific Will Generate Volume but Remain Highly Uneven

A South Korean nationwide cohort study identified 252,810 incident RVO cases between 2011 and 2020. The weighted mean incidence reached 50.99 per 100,000 person-years and peaked among people aged 75–79.

The data confirm substantial age-related exposure in a region with rapidly expanding elderly populations. However, access differs sharply across South Korea, Japan, China, India, Singapore, and lower-income markets.

South Korea and Japan have stronger specialist and imaging infrastructure, while India remains more dependent on affordability and out-of-pocket purchasing. Bayer’s 44% Eylea price reduction and Zydus’ Anyra launch in 2026 reflect the stronger role of pricing in Indian adoption.

Asia-Pacific will provide a large treatment pool, but no single commercial model will cover the region. Premium durability products will gain traction in reimbursed markets, while biosimilars and price-reduced brands will drive expansion in cost-sensitive systems.

 

Early Pipeline Programs Will Not Displace Anti-VEGF in the Near Term

The TRUST phase I/II study evaluated intravitreal autologous CD34-positive bone-marrow-derived stem cells in 16 eyes with vision loss associated with CRVO.

The procedure was feasible in this small study, but the results were mainly about safety rather than treatment benefit. Fifteen of the 16 treated eyes developed new floaters, and one serious ocular event was linked to worsening of the underlying CRVO.

Annexin Pharmaceuticals reported in February 2026 that ANXV, a recombinant Annexin A5 protein, remained in phase 2 ophthalmology development for RVO and diabetic retinopathy.

These programs are still too early to affect the near-term market. Anti-VEGF therapies will remain the main treatment category through 2032, while newer mechanisms are unlikely to contribute meaningful revenue during the forecast period.

 

Competitive Positioning Will Divide Between Durability and Affordability

Regeneron and Bayer are protecting their retina franchise through Eylea HD. U.S. sales of the high-dose product reached USD 1.6 billion in 2025, while FDA, European, and AAO recognition strengthened its position in RVO.

Roche is competing through Vabysmo’s expanding label, extended dosing data, reimbursement wins, and CHF 2.9 billion in 2025 retina sales.

Yesafili, Opuviz, Anyra, and other biosimilars are positioned to gain share where affordability limits treatment initiation or persistence. Bevacizumab will continue to influence pricing because SCORE2 supports its clinical relevance in selected RVO populations.

The market is likely to divide based on cost and treatment burden. Retina practices may favor longer-acting branded drugs when fewer injection visits help manage patient volume. Biosimilars and bevacizumab will remain important in settings where formularies, patient affordability, or out-of-pocket costs determine treatment choice.

 

Strategic Outlook: Durability Will Drive Branded Growth While Price Expands the Treated Population

The RVO treatment market will remain anchored in anti-VEGF therapy because macular edema creates recurring injection and monitoring demand. Real-world evidence showing approximately seven first-year injections and continued treatment in more than two-thirds of available patients at year five supports a durable revenue base.

Eylea HD and Vabysmo are shifting branded competition toward longer intervals. QUASAR data favour aflibercept 8 mg as a franchise-conversion product, while BALATON and COMINO support Roche’s challenge across a broader retina portfolio.

Biosimilars, bevacizumab, and regional price cuts will continue to reduce acquisition costs. These products can expand treatment access but will intensify pressure on revenue per injection.

The largest commercial gains will come from improving treatment initiation and keeping patients under care beyond the loading phase. Products that reduce injection and clinic burden while preserving visual outcomes will gain branded share. Lower-cost therapies will expand the addressable market where affordability remains the main barrier.

Through 2032, durability will determine premium positioning, while pricing and reimbursement will determine how much of the diagnosed RVO population enters and remains in treatment.

 

Retinal Vein Occlusion Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.57 Billion
Revenue Forecast in 2032	USD 3.90 Billion
Overall Growth Rate	CAGR of 6.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Anti-VEGF Molecule Type, By Disease Type, By Treatment Setting, By Distribution Channel, By Geography
By Treatment Type	Anti-VEGF Therapy, Corticosteroid Therapy, Laser Therapy, Investigational & Disease-Modifying Therapies
By Anti-VEGF Molecule Type	Aflibercept, Faricimab, Ranibizumab, Bevacizumab, Biosimilar Anti-VEGF Agents
By Disease Type	Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
By Treatment Setting	Retina Specialty Centers, Ophthalmology Clinics, Hospitals, Ambulatory Retina Care Settings
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Clinic-Based Procurement, Retail Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Growing RVO prevalence among aging populations, rising hypertension-related retinal complications, increasing adoption of longer-interval anti-VEGF therapies, expanding biosimilar competition, improving retina care infrastructure, and demand for reduced injection burden solutions
Customization Option	Available upon request